Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors.

Détails

Ressource 1Télécharger: 1-s2.0-S0305737221001304-main (2).pdf (1833.43 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0
ID Serval
serval:BIB_63661F460346
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors.
Périodique
Cancer treatment reviews
Auteur⸱e⸱s
Arangalage D., Degrauwe N., Michielin O., Monney P. (co-dernier), Özdemir B.C.
ISSN
1532-1967 (Electronic)
ISSN-L
0305-7372
Statut éditorial
Publié
Date de publication
11/2021
Peer-reviewed
Oui
Volume
100
Pages
102282
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Immune checkpoint inhibitors (ICIs) and BRAF and MEK inhibitors (BRAFi/MEKi) have drastically improved the outcome of melanoma patients. ICIs can induce myocarditis, a rare immune related adverse event (irAE) with an estimated lethality of 50%. BRAFi/MEKi may induce left ventricular ejection fraction decrease, hypertension or QT interval prolongation. While the BRAFi/MEKi induced cardiotoxicity is often reversible upon treatment discontinuation or dose adaptation and symptomatic therapy is often sufficient to restore cardiac function, the treatment of ICI-induced myocarditis mainly relies on high dose corticosteroids. There is no established therapy for steroid resistant myocarditis, yet various drugs have been reported to improve outcome. Shared epitopes between melanoma cells and cardiac tissue are thought to underlie the development of ICIs induced myocarditis. The mechanism of BRAFi/MEKi induced cardiotoxicity appears to be related to the Ras-Raf-MEK-ERK pathway in cardiomyocyte repair, survival and proliferation. With the emerging application of ICI-BRAFi/MEKi combinations, so called triplet therapies, differentiating between these two types of cardiotoxicity will become important for appropriate patient management. In this article we provide a summary of the existing literature on the pathophysiology, diagnosis and management of cardiotoxicity of melanoma therapies.
Mots-clé
BRAF inhibitor, Cardiotoxicity, Heart failure, Hypertension, Immune checkpoint inhibitors, Immune related adverse events, MEK inhibitor, Melanoma, Myocarditis, Pathophysiology
Pubmed
Web of science
Open Access
Oui
Création de la notice
15/09/2021 9:58
Dernière modification de la notice
08/02/2024 7:17
Données d'usage